Patients with hormone receptor– and HER2-positive breast cancer were randomly assigned to receive docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) with or without estrogen deprivation therapy. This evidence concerns the gene ERBB2 and breast cancer.